Vivesto AB (VIVE) - Total Assets
Based on the latest financial reports, Vivesto AB (VIVE) holds total assets worth Skr177.85 Million SEK (≈ $19.14 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vivesto AB - Total Assets Trend (2004–2025)
This chart illustrates how Vivesto AB's total assets have evolved over time, based on quarterly financial data. Also see market cap of Vivesto AB for the company's overall valuation and market capitalisation.
Vivesto AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Vivesto AB's total assets of Skr177.85 Million consist of 3.7% current assets and 96.3% non-current assets. Review how much debt does Vivesto AB carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 1.4% |
| Accounts Receivable | Skr3.40 Million | 2.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr143.24 Million | 96.1% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Vivesto AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See VIVE stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vivesto AB's current assets represent 3.7% of total assets in 2025, a decrease from 6.8% in 2004.
- Cash Position: Cash and equivalents constituted 1.4% of total assets in 2025, down from 5.5% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 96.0% of total assets, an increase from 92.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 96.1% of total assets.
Vivesto AB Competitors by Total Assets
Key competitors of Vivesto AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Vivesto AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.06 | 1.45 | 1.68 |
| Quick Ratio | 3.06 | 1.45 | 1.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr23.25 Million | Skr9.41 Million | Skr117.39 Million |
Vivesto AB - Advanced Valuation Insights
This section examines the relationship between Vivesto AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.60 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -13.8% |
| Total Assets | Skr149.04 Million |
| Market Capitalization | $10.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vivesto AB's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Vivesto AB's assets decreased by 13.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vivesto AB (2004–2025)
The table below shows the annual total assets of Vivesto AB from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr149.04 Million ≈ $16.04 Million |
-13.79% |
| 2024-12-31 | Skr172.88 Million ≈ $18.60 Million |
-21.66% |
| 2023-12-31 | Skr220.67 Million ≈ $23.75 Million |
-37.99% |
| 2022-12-31 | Skr355.88 Million ≈ $38.30 Million |
-40.12% |
| 2021-12-31 | Skr594.31 Million ≈ $63.96 Million |
-31.18% |
| 2020-12-31 | Skr863.54 Million ≈ $92.93 Million |
-14.11% |
| 2019-12-31 | Skr1.01 Billion ≈ $108.19 Million |
+55.54% |
| 2018-12-31 | Skr646.38 Million ≈ $69.56 Million |
+13.78% |
| 2017-12-31 | Skr568.08 Million ≈ $61.13 Million |
+8.91% |
| 2016-12-31 | Skr521.58 Million ≈ $56.13 Million |
+1.16% |
| 2015-12-31 | Skr515.58 Million ≈ $55.48 Million |
+0.20% |
| 2014-12-31 | Skr514.57 Million ≈ $55.38 Million |
+9.86% |
| 2013-12-31 | Skr468.38 Million ≈ $50.41 Million |
+5.21% |
| 2012-12-31 | Skr445.18 Million ≈ $47.91 Million |
+27.26% |
| 2011-12-31 | Skr349.81 Million ≈ $37.64 Million |
+9.21% |
| 2010-12-31 | Skr320.32 Million ≈ $34.47 Million |
+78.30% |
| 2009-12-31 | Skr179.65 Million ≈ $19.33 Million |
+85.02% |
| 2008-12-31 | Skr97.10 Million ≈ $10.45 Million |
+10.75% |
| 2007-12-31 | Skr87.67 Million ≈ $9.43 Million |
-27.42% |
| 2006-12-31 | Skr120.79 Million ≈ $13.00 Million |
+89.64% |
| 2005-12-31 | Skr63.69 Million ≈ $6.85 Million |
+76.63% |
| 2004-12-31 | Skr36.06 Million ≈ $3.88 Million |
-- |
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantri… Read more